Founded Year

2013

Stage

Series C | Alive

Total Raised

$203.6M

Last Raised

$110M | 1 yr ago

About Aetion

Aetion delivers real-world evidence for life sciences companies, payers, at-risk providers, and regulatory agencies. The Aetion Evidence Platform analyzes data from the real world to produce rapid and scientifically validated answers on treatments, costs, and outcomes. Aetion informs health care's most critical decisions - what works best, for whom, and when - to guide treatment development, commercialization, and payment values into health care's modern era.

Aetion Headquarter Location

5 Penn Plaza 7th Floor

New York, New York, 10001,

United States

646-513-2200

ESPs containing Aetion

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

EXECUTION STRENGTHMARKET STRENGTHLEADERHIGHFLIEROUTPERFORMERCHALLENGER
Healthcare / Biopharmaceuticals

Companies in this market offer alternative datasets that can supplement clinical trial data and improve the likelihood of trial success. These companies collect data from a variety of sources, such as patient registries, EHRs, insurance databases, social media, and patient research networks.

Aetion named as Leader among 15 other companies, including Datavant, Syapse, and Evidation.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Aetion

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Aetion is included in 7 Expert Collections, including Clinical Trials Tech.

C

Clinical Trials Tech

326 items

Companies developing products and services to streamline drug R&D, from drug discovery, pre-clinical testing, and clinical trials.

C

Conference Exhibitors

5,501 items

HLTH is a healthcare event bringing together startups and large companies from pharma, health insurance, business intelligence, and more to discuss the shifting landscape of healthcare

D

Digital Health 150

300 items

2019's cohort of the most promising digital health startups transforming the healthcare industry

V

Value-Based Care & Population Health

860 items

The VBC & Population Health collection includes companies that enable and deliver care models that address the health needs for defining populations along the continuum of care, including in the community setting, through participation, engagement, and targeted interventions.

D

Digital Health

12,795 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

C

Clinical Trials Tech Market Map

108 items

This CB Insights Tech Market Map highlights 100+ clinical trials tech companies that are addressing 8 distinct technology priorities that pharmaceutical companies and CROs face.

Aetion Patents

Aetion has filed 4 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/30/2015

5/18/2021

Database management systems, Data management, Relational database management systems, Free database management systems, Databases

Grant

Application Date

12/30/2015

Grant Date

5/18/2021

Title

Related Topics

Database management systems, Data management, Relational database management systems, Free database management systems, Databases

Status

Grant

Latest Aetion News

07:00 EDT National Evaluation System for health Technology Coordinating Center (NESTcc) Partners with Aetion to Transform the Ro...

Apr 21, 2022

News provided by Share this article Aetion logo (PRNewsfoto/Aetion) Leading RWE platform Aetion to support the development of NESTcc's Analytics Core offering, contributing to NESTcc's RWE initiatives ARLINGTON, Va. and NEW YORK, April 21, 2022 /PRNewswire/ -- Today, the National Evaluation System for health Technology Coordinating Center ( NESTcc ), an initiative of the Medical Device Innovation Consortium ( MDIC ), announced a first-of-its-kind, five-year strategic partnership with Aetion , a leading real-world evidence (RWE) analytics provider, to advance the use of RWE in the medical device and diagnostics ecosystem. "NESTcc has made great strides over the last several years to advance the use of RWE," said Sandra Siami, Senior Vice President at MDIC and head of NESTcc. "As we continue to develop the national evaluation system and establish standards for evidence generation, Aetion brings to NESTcc best-in-class analytics technology and expertise to accelerate RWE innovation and scale." As part of this strategic partnership, Aetion will serve as a collaborator in the development of NESTcc's Analytics Core, an array of services, capabilities and partners that enhance the ability to catalyze RWE in medical devices. Aetion's technology, the Aetion Evidence Platform®, will be used as an analytics engine in sponsor-funded NESTcc evidence generation. Under the agreement, NESTcc will also leverage Aetion's expertise in the development and execution of the Active Surveillance Program, part of the U.S. Food and Drug Administration's (FDA) 2018 Medical Device Safety Action Plan . In 2016, the FDA awarded a cooperative agreement to MDIC to establish NESTcc, and the Agency continues to be an active participant. Leading the Analytics Core development efforts are NESTcc's Sandra Siami; Daniel Caños, Director, Office of Clinical Evidence and Analysis, OPEQ, Center for Devices and Radiological Health (CDRH) at the FDA; and Christian Howell, VP/GM, Medical Devices and Diagnostics at Aetion. "This partnership reflects CDRH's continued efforts to prioritize RWE in decision making as it relates to bringing new products to market, evaluating the safety and effectiveness of existing products for new uses, and ongoing surveillance of the performance and safety of products once approved," said Jeff Shuren, Director of the FDA's Center for Devices and Radiological Health. "As NESTcc, Aetion and CDRH continue to build upon the industry's use of real-world data, the goal will always be to protect and promote public health." "Providing the medical device and diagnostic ecosystem with a platform to generate high-quality evidence quickly and efficiently enables better clinical outcomes. We are honored to work with a leader like NESTcc, with a demonstrated track record of improving outcomes for patients," said Carolyn Magill, CEO, Aetion. "We have the opportunity to transform how data from medical devices can be used to generate insights." Aetion first began working with the FDA in May 2020 through a research collaboration to advance the understanding of and response to COVID-19 using real-world data. In October 2021 , the Agency then announced that it would contract with Aetion to develop a framework and system of studies for the rapid assessment of COVID-19 inpatient medical products using the Aetion Evidence Platform®. About the National Evaluation System for health Technology Coordinating Center In 2016, the U.S. Food and Drug Administration (FDA) awarded the Medical Device Innovation Consortium (MDIC) funding to establish the National Evaluation System for health Technology Coordinating Center (NESTcc). NESTcc is advancing the use of real-world evidence (RWE) in medical devices for regulatory decision-making and committed to transforming the way medical device technologies are tested, approved and monitored. The Coordinating Center combines RWE system infrastructure with the unparalleled expertise of its network collaborators to accelerate patients' access to safe and effective medical technology and provide Quality Evidence by Design™. For more information, visit http://www.nestcc.org . About the Medical Device Innovation Consortium Founded in 2012, the Medical Device Innovation Consortium (MDIC) is the first public-private partnership created with the sole objective of advancing medical device regulatory science throughout the total product life cycle. MDIC's mission is to promote public health through science and technology and to enhance trust and confidence among stakeholders. MDIC works in the pre-competitive space to facilitate development of methods, tools and approaches that enhance understanding and improve evaluation of product safety, quality and effectiveness. Its initiatives improve product safety and patient access to cutting-edge medical technology while reducing cost and time to market. For more information, visit http://www.mdic.org . Funding for NESTcc was made possible, in part, by the U.S. Food and Drug Administration through grant (U01FD006292). Views expressed in written materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does any mention of trade names, commercial practices, or organization imply endorsement by the United States Government. About Aetion Aetion is a healthcare analytics company that delivers real-world evidence for the manufacturers, purchasers, and regulators of medical treatments and technologies. The Aetion Evidence Platform® analyzes data from the real world to produce transparent, rapid, and scientifically validated answers on safety, effectiveness, and value. Founded by Harvard Medical School faculty members with decades of experience in epidemiology and health outcomes research, Aetion informs healthcare's most critical decisions—what works best, for whom, and when—to guide product development, commercialization, and payment innovation. Learn more at aetion.com and follow us at @aetioninc .

Aetion Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Aetion Rank

  • When was Aetion founded?

    Aetion was founded in 2013.

  • Where is Aetion's headquarters?

    Aetion's headquarters is located at 5 Penn Plaza, New York.

  • What is Aetion's latest funding round?

    Aetion's latest funding round is Series C.

  • How much did Aetion raise?

    Aetion raised a total of $203.6M.

  • Who are the investors of Aetion?

    Investors of Aetion include Flare Capital Partners, New Enterprise Associates, Foresite Capital, B Capital Group, Warburg Pincus and 15 more.

  • Who are Aetion's competitors?

    Competitors of Aetion include Unlearn, MDisrupt, Holmusk, Owkin, Panalgo and 11 more.

You May Also Like

ConcertAI Logo
ConcertAI

ConcertAI specializes in integrated clinical RWD, AI solutions and outcomes science with a large RWD oncology dataset. ConcertAI develops a medical research tool suite that offers care-based oncology research and data analytics.

T
TriNetX

TriNetX is the global health research network that optimizes clinical research and enables discoveries through the creation of real-world evidence. TriNetX combines real-time access to longitudinal clinical data with analytics to answer complex research questions.

Tempus Logo
Tempus

Tempus builds a library of molecular and clinical data as well as a corresponding operating system for data accessibility and use. The company enables physicians to deliver personalized cancer care for patients through its interactive analytical and machine learning platform. It provides genomic sequencing services and molecular and therapeutic data analysis to empower physicians to make real-time, data-driven decisions.

xCures Logo
xCures

xCures is a health technology company that has created an AI- and expert-supported Perpetual Clinical Trial platform that continuously learns from all patients, on all treatments, all the time. It provides patients, and their physicians, with individualized treatment options and facilitates access via reimbursement, clinical trials and expanded-access support.

Syapse Logo
Syapse

Syapse develops applications that enable the use of omics profiles in diagnosing and treating patients at diagnostic companies, research institutions, medical centers, and payers. The Syapse Discovery application provides an end-to-end solution for companies and laboratories deploying next-generation sequencing-based diagnostics, from patient sample received to physician report delivered. Discovery's configurable semantic data structure enables users to bring omics data together with traditional medical information to develop and deliver diagnostic tests. The platform's open interfaces enable bioinformaticians and biologists to use their favorite computational tools and annotations.

Owkin Logo
Owkin

Owkin specializes in AI technologies applied to clinical research with the aim of developing better drugs and treatments for patients. The company's purpose is to empower researchers in hospitals, universities and the biopharma industry to i) understand why drug efficacy varies from patient to patient, ii) improve the drug development process and iii) to help identify key drugs and treatments for each individual patient to improve patient outcomes. The company's precision medicine platform aims to enable medical insights for drug discovery and development by connecting life sciences firms with academic researchers and hospitals. The Owkin platform aims to enable partners to uncover siloed datasets while maintaining patient privacy and securing proprietary data using Federated Learning and innovative collaborative AI technology.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.